SAB Biotherapeutics Investor Relations Material

SAB Biotherapeutics Inc. is a biotechnology company focused on developing immunotherapies using its proprietary DiversitAb platform. The company specializes in producing targeted, fully human polyclonal antibodies for infectious diseases, autoimmune disorders, and other conditions. SAB Biotherapeutics leverages genetically engineered cattle to generate scalable and high-potency antibody treatments. The company is headquartered in Sioux Falls, South Dakota, and its shares are listed on the NASDAQ.